Toll Free: 1-888-928-9744
Published: Sep, 2014 | Pages:
26 | Publisher: Global Markets Direct
Industry: Pharmaceutical | Report Format: Electronic (PDF)
SBI Biotech Co., Ltd. - Product Pipeline Review - 2014 Summary Global Markets Direct's, 'SBI Biotech Co., Ltd. - Product Pipeline Review - 2014', provides an overview of the SBI Biotech Co., Ltd.'s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of SBI Biotech Co., Ltd.'s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides brief overview of SBI Biotech Co., Ltd. including business description, key information and facts, and its locations and subsidiaries - The report reviews current pipeline of SBI Biotech Co., Ltd.'s human therapeutic division and enlists all their major and minor projects - The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones - Special feature on out-licensed and partnered product portfolio - The report summarizes all the dormant and discontinued pipeline projects - Latest company statement - Latest news and deals relating to the SBI Biotech Co., Ltd.'s pipeline products Reasons to buy - Evaluate SBI Biotech Co., Ltd.'s strategic position with total access to detailed information on its product pipeline - Assess the growth potential of SBI Biotech Co., Ltd. in its therapy areas of focus - Identify new drug targets and therapeutic classes in the SBI Biotech Co., Ltd.'s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas - Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps - Develop strategic initiatives by understanding the focus areas of SBI Biotech Co., Ltd. and exploit collaboration and partnership opportunities - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Plan mergers and acquisitions effectively by identifying the most promising pipeline of SBI Biotech Co., Ltd. - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Explore the dormant and discontinued projects of SBI Biotech Co., Ltd. and identify potential opportunities in those areas - Avoid Intellectual Property Rights related issues
Table of Contents Table of Contents 2 List of Tables 3 List of Figures 3 SBI Biotech Co., Ltd. Snapshot 4 SBI Biotech Co., Ltd. Overview 4 Key Information 4 Key Facts 4 SBI Biotech Co., Ltd. - Research and Development Overview 5 Key Therapeutic Areas 5 SBI Biotech Co., Ltd. - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Pipeline Products - Out-Licensed Products 9 Out-Licensed Products/Combination Treatment Modalities 10 SBI Biotech Co., Ltd. - Pipeline Products Glance 11 SBI Biotech Co., Ltd. - Clinical Stage Pipeline Products 11 Phase II Products/Combination Treatment Modalities 11 Phase I Products/Combination Treatment Modalities 12 SBI Biotech Co., Ltd. - Early Stage Pipeline Products 13 Preclinical Products/Combination Treatment Modalities 13 SBI Biotech Co., Ltd. - Drug Profiles 14 MelVax 14 Product Description 14 Mechanism of Action 14 R&D Progress 14 GNKG-168 15 Product Description 15 Mechanism of Action 15 R&D Progress 15 Antibody to Inhibit BST-2 for Oncology and Autoimmune Disorders 17 Product Description 17 Mechanism of Action 17 R&D Progress 17 GNKS-356 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Small Molecule to Inhibit Cdc7/ASK for Oncology 19 Product Description 19 Mechanism of Action 19 R&D Progress 19 SBI Biotech Co., Ltd. - Pipeline Analysis 20 SBI Biotech Co., Ltd. - Pipeline Products by Target 20 SBI Biotech Co., Ltd. - Pipeline Products by Route of Administration 21 SBI Biotech Co., Ltd. - Pipeline Products by Molecule Type 22 SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action 23 SBI Biotech Co., Ltd. - Locations And Subsidiaries 24 Head Office 24 Other Locations & Subsidiaries 24 Appendix 25 Methodology 25 Coverage 25 Secondary Research 25 Primary Research 25 Expert Panel Validation 25 Contact Us 26 Disclaimer 26
List of Tables SBI Biotech Co., Ltd., Key Information 4 SBI Biotech Co., Ltd., Key Facts 4 SBI Biotech Co., Ltd. - Pipeline by Indication, 2014 6 SBI Biotech Co., Ltd. - Pipeline by Stage of Development, 2014 7 SBI Biotech Co., Ltd. - Monotherapy Products in Pipeline, 2014 8 SBI Biotech Co., Ltd. - Out-Licensed Products in Pipeline, 2014 9 SBI Biotech Co., Ltd. - Out-Licensed Products/ Combination Treatment Modalities, 2014 10 SBI Biotech Co., Ltd. - Phase II, 2014 11 SBI Biotech Co., Ltd. - Phase I, 2014 12 SBI Biotech Co., Ltd. - Preclinical, 2014 13 SBI Biotech Co., Ltd. - Pipeline by Target, 2014 20 SBI Biotech Co., Ltd. - Pipeline by Route of Administration, 2014 21 SBI Biotech Co., Ltd. - Pipeline by Molecule Type, 2014 22 SBI Biotech Co., Ltd. - Pipeline Products by Mechanism of Action, 2014 23 SBI Biotech Co., Ltd., Subsidiaries 24
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.